Ken Griffin Savara Inc Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $398,208 - $580,992	108,800 Added 2092.31%	114,000 $459,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $10,056 - $13,416	2,400 Added 85.71%	5,200 $25,000
Q4 2023 Feb 14, 2024	SELL	$3.18 - $4.9 $4,134 - $6,370	-1,300 Reduced 31.71%	2,800 $13,000
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.88 $15,147 - $19,788	-5,100 Reduced 55.43%	4,100 $15,000
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $3,887 - $7,452	-2,300 Reduced 20.0%	9,200 $29,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.82 $59,680 - $105,186	-37,300 Reduced 76.43%	11,500 $22,000
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.64 $30,858 - $45,592	27,800 Added 132.38%	48,800 $75,000
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $7,888 - $10,904	5,800 Added 38.16%	21,000 $33,000

145

147M

280K

798K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $479M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.